The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Official Title: A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Study ID: NCT01486368
Brief Summary: This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
Detailed Description: To assess the efficacy (response rate, complete and partial) of PF-03446962 given by IV infusion Day 1 of a 2 week cycle (14 days = 1 cycle) in patients with advanced malignant pleural mesothelioma and previously treated with cytotoxic therapy. To assess the toxicity, safety and tolerability of PF-03446962. To assess the duration of response or stable disease, stable disease rate, progression-free, median and overall survival rates. To collect tissue and blood for banking and correlative science evaluation.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Cross Cancer Institute, Edmonton, Alberta, Canada
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
CancerCare Manitoba, Winnipeg, Manitoba, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Name: Quincy Chu
Affiliation: Cross Cancer Institute, Edmonton, AB Canada
Role: STUDY_CHAIR
Name: Paul Wheatley-Price
Affiliation: Ottawa Health Research Institute - General Division, Ottawa ON Canada
Role: STUDY_CHAIR